The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Background of SANOVO trial for patients with advanced NSCLC
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, talks about the study design of the SANOVO trial (NCT05009836), a Phase III clinical study investigating the efficacy of osimertinib, combined with savolitinib or placebo, in patients with EGFRm+/MET+ non-small cell lung cancer (NSCLC). Dr Zhou discusses the background of savolitinib and its purpose in the study, alongside the primary endpoint of the trial, which was progression-free survival (PFS). She mentions other important secondary endpoints, such as the response rate, overall survival (OS) and safety of the trial. Dr Zhou hopes that results from this study will enable a new type of standard treatment for this specific population of NSCLC patients. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
